Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol.
- 1 January 2000
- journal article
- clinical trial
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 5 (1) , 16-24
- https://doi.org/10.1080/13625180008500376
Abstract
To investigate ovulation inhibition with drospirenone, a novel progestogen that has a profile similar to natural progesterone, when given alone or in combination with ethinylestradiol.Keywords
This publication has 7 references indexed in Scilit:
- The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potentialContraception, 1996
- Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity: Pharmacological characterization in animal modelsContraception, 1995
- Ultrasound evaluation of ovarian activity under oral contraceptivesContraception, 1993
- Dihydrospirorenone, a New Progestogen with Antimineralocorticoid Activity: Effects on Ovulation, Electrolyte Excretion, and the Renin-Aldosterone System in Normal WomenJournal of Clinical Endocrinology & Metabolism, 1991
- Aldosterone antagonists. 4. Synthesis and activities of steroidal 6,6-ethylene-15,16-methylene 17-spirolactonesJournal of Medicinal Chemistry, 1991
- Effects of Progesterone and Four Synthetic Progestagens on Sodium Balance and the Renin-Aldosterone System in Man*†Journal of Clinical Endocrinology & Metabolism, 1974
- PLASMA ANGIOTENSIN II AND ALDOSTERONE EXCRETION DURING THE MENSTRUAL CYCLEActa Endocrinologica, 1970